Výsledky vyhledávání - "Pierre Broqua"

Akademický článek

The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis

Autor: Michael P. Cooreman, Javed Butler, Robert P. Giugliano, Faiez Zannad, Lucile Dzen, Philippe Huot-Marchand, Martine Baudin, Daniel R. Beard, Jean-Louis Junien, Pierre Broqua, Manal F. Abdelmalek, Sven M. Francque

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)

Abstract Lanifibranor, a pan-PPAR agonist, improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH), who have poor cardiometabolic health (CMH) and cardiovascular events as major mortality cause. NATIVE trial

Externí odkaz: https://doaj.org/article/a8349f7dd9df4b16ac7569db5e4e8c59

Zobrazit plný text záznamu

Akademický článek

Biomarkers of Glycosaminoglycans (GAG) accumulation in patients with mucopolysaccharidosis type VI—LeukoGAG, Corneal Opacification (COM) and Carotid Intima Media Thickening (CIMT)

Autor: Young Bae Sohn, Raymond Wang, Jane Ashworth, Pierre Broqua, Mireille Tallandier, Jean-Louis Abitbol, Erin Jozwiak, Laura Pollard, Timothy C. Wood, Tariq Aslam, Paul R. Harmatz

Publikováno v: Molecular Genetics and Metabolism Reports, Vol 38, Iss , Pp 101041- (2024)

Mucopolysaccharidosis type VI (MPS VI) is an autosomal recessive lysosomal storage disorder characterized by deficient activity of arylsulfatase B enzyme (ASB) resulting in cellular accumulation of dermatan sulfate (DS) and chondroitin sulfate (CS) t

Externí odkaz: https://doaj.org/article/efb44fff9b354619a473658aafb0ccd6

Zobrazit plný text záznamu

Akademický článek

Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models

Autor: Pascale Tuyaa-Boustugue, Ingrid Jantzen, Haoyue Zhang, Sarah P. Young, Pierre Broqua, Mireille Tallandier, Eugeni Entchev

Publikováno v: Molecular Genetics and Metabolism Reports, Vol 37, Iss , Pp 101011- (2023)

Deficiencies of lysosomal enzymes responsible for the degradation of glycosaminoglycans (GAG) cause pathologies commonly known as the mucopolysaccharidoses (MPS). Each type of MPS is caused by a deficiency in a specific GAG-degrading enzyme and is ch

Externí odkaz: https://doaj.org/article/39015b4be7194098910689d76cf2f4c1

Zobrazit plný text záznamu

Akademický článek

CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas

Publikováno v: Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)

Abstract Tumor-infiltrating CD8 + T cells progressively lose functionality and fail to reject tumors. The underlying mechanism and re-programing induced by checkpoint blockers are incompletely understood. We show here that genetic ablation or pharmac

Externí odkaz: https://doaj.org/article/22bfa2b345944a4983ce8b49f08339e4

Zobrazit plný text záznamu

Akademický článek

The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

Autor: Emma Derrett-Smith, Kristina E. N. Clark, Xu Shiwen, David J. Abraham, Rachel K. Hoyles, Olivier Lacombe, Pierre Broqua, Jean Louis Junien, Irena Konstantinova, Voon H. Ong, Christopher P. Denton

Publikováno v: Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-13 (2021)

Abstract Background The TβRII∆k-fib transgenic (TG) mouse model of scleroderma replicates key fibrotic and vasculopathic complications of systemic sclerosis through fibroblast-directed upregulation of TGFβ signalling. We have examined peroxisome

Externí odkaz: https://doaj.org/article/29917a595917451aa674f32d4bacb9c8

Zobrazit plný text záznamu

Akademický článek

Author Correction: CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)

Externí odkaz: https://doaj.org/article/103f997df819424ea57c7cf97b5024dc

Zobrazit plný text záznamu

Akademický článek

Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.

Autor: Eugeni Entchev, Ingrid Jantzen, Philippe Masson, Stephanie Bocart, Bruno Bournique, Jean-Michel Luccarini, Andre Bouchot, Olivier Lacombe, Jean-Louis Junien, Pierre Broqua, Mireille Tallandier

Publikováno v: PLoS ONE, Vol 15, Iss 5, p e0233032 (2020)

Mucopolysaccharidoses are a class of lysosomal storage diseases, characterized by enzymatic deficiency in the degradation of specific glycosaminoglycans (GAG). Pathological accumulation of excess GAG leads to multiple clinical symptoms with systemic

Externí odkaz: https://doaj.org/article/18aaeaa92fd84ae2983028dab3ec1275

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání